Dr. Kulkarni obtained his PhD from the University of British Columbia and has over 10 years of academic and industry experience in the nanoparticle drug delivery field.
He has published over 35 peer-reviewed articles in prestigious journals and co-inventor on 14 patents. He has held many awards, including the inaugural Nanomedicines Innovation Network’s postdoctoral fellowship in gene therapy.
Dr. Kulkarni’s research has focused on the role of the various lipid components in LNP and the biophysics that governs particle formation. His work has contributed to clinical translation, including scale-up and manufacturing of LNP systems in accordance with GLP and GMP regulations.
Dr. Kulkarni is a leader in the design and development of lipid nanoparticle (LNP) formulations of small molecule and nucleic acid therapeutics. He currently serves as the Chief Scientific Officer of NanoVation Therapeutics (NTx), an LNP-RNA formulation developer.